NL-OMON42748
Completed
Not Applicable
A drug-drug interaction study between the novel anti-HCV agent DAclatasvir and The antidiabetic agent mEtformine in healthy volunteers. - DATE-3
Apotheek0 sites20 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- diabetes mellitus
- Sponsor
- Apotheek
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects must meet all of the following inclusion criteria to be eligible for participation in this study
- •1\. Subject is at least 18 and not older than 55 years at screening.
- •2\. Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to Day 1\.
- •3\. Subject has a Quetelet Index (Body Mass Index) of 18 to 35 kg/m2, extremes included.
- •4\. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
- •5\. Subject is in good age\-appropriate health condition as established by medical history, physical examination, and electrocardiography, results of biochemistry, haematology and urinalysis testing within 4 weeks prior to Day 1\. Results of biochemistry, haematology and urinalysis testing should be within the laboratory's reference ranges (see Appendix A). If laboratory results are not within the reference ranges, the subject is included on condition that the Investigator judges that the deviations are not clinically relevant. This should be clearly recorded.
- •6\. Subject has a normal blood pressure and pulse rate, according to the Investigator's judgement.
Exclusion Criteria
- •A potential subject who meets any of the following criteria will be excluded from partici\-pation in this study:
- •1\. Creatinine clearance below 60mL/min.
- •2\. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
- •3\. Positive HIV test.
- •4\. Positive hepatitis B or C test.
- •5\. Pregnant female (as confirmed by an hCG test performed less than 4 weeks before day 1\) or breastfeeding female. Female subjects of childbearing potential without adequate contraception, e.g. hysterectomy, bilateral tubal ligation, (non\-hormonal) intrauterine device, total abstinence, double barrier methods, or two years post\-menopausal. They must agree to take precautions in order to prevent a pregnancy throughout the entire conduct of the study.
- •6\. Therapy with any drug (for two weeks preceding Day 1\), except for acetaminophen (max 2 gram/day).
- •7\. Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), psychiatric disorders, gastro\-intestinal disorders, renal and hepatic disorders (increased ALAT/ASAT), hormonal disorders (especially diabetes mellitus), coagulation disorders.
- •8\. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
- •9\. History of or current abuse of drugs, alcohol or solvents.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A drug-drug interaction study between the novel anti-HCV agent daclatasvir and the antiretroviral agents atazanavir/ritonavir or atazanavir/cobicistat in healthy volunteers.HCVHepatitis CHIV10047438NL-OMON42827Apotheek16
Active, not recruiting
Not Applicable
Study on the pharmacodynamic interactions between propofol and sevoflurane during induction of anesthesia.AnesthesiaEUCTR2005-004632-40-BEniversity Hospital Ghent60
Completed
Phase 1
Pharmacokinetic drug-drug interaction study between oral 300 mg netupitant/0.50 mg palonosetron fixed dose combination (Akynzeo®) and oral dexamethasone to evaluate the duration of the CYP3A4 inhibition in healthy subjectsInhibitory effect on CYP3A4Not ApplicableISRCTN93845260Helsinn Healthcare SA24
Completed
Not Applicable
The pharmacokinetic study of drug interaction between metformin and pyrimethamine from microdose to clinical dose in adult healthy volunteershealthy male subjectsJPRN-UMIN000002739Clinical trial Center,Kitasato University East Hospital8
Completed
Phase 1
Drug-drug interaction in the co-administration of the antiretroviral drugs and the antischistomicide praziquantelHIV/AIDSschistosomiasisPACTR202102566734864AiBST32